The Indian fertility services market welcomed a significant milestone today as Gaudium IVF and Women Health Ltd. Launched its initial public offering (IPO) on February 20, 2026. The IPO, the first of its kind for a company in the fertility care sector in India, aims to raise ₹165 crore. Early indicators suggest strong investor interest, with the issue already booked 88% as of today, and the grey market premium (GMP) signaling a potential 11% listing pop. This Gaudium IVF IPO is drawing attention not only for its sector-first status but also for its ambitious expansion plans.
Prior to the public offering, Gaudium IVF secured ₹49.5 crore from anchor investors on Thursday, February 19, according to a circular uploaded on the BSE website. These investors include MERU Investment Fund PCC-CELL, Sanshi Fund I, Hornbill Orchid India Fund, and Carnelian India Multi Strategy Fund. The company allocated 62,65,860 shares to these investors at ₹79 apiece, solidifying early confidence in the company’s prospects. The funds raised through the IPO will be strategically allocated to establish 19 new IVF centers across India, repay existing debt, and support general corporate needs.
Expanding Access to Fertility Care
Founded by Manika Khanna, Gaudium IVF has established a “hub-and-spoke” model, currently operating seven hubs and 28 spokes across multiple states. This network allows the company to reach a broad patient base, and the planned expansion aims to extend access to affordable IVF services, particularly in underserved regions. The company’s financial performance demonstrates a growth trajectory, reporting revenue of ₹70.72 crore and a Profit After Tax (PAT) of ₹19.13 crore for the financial year ending March 31, 2025. This represents an increase from the ₹47.89 crore revenue and ₹10.31 crore PAT reported in FY24, indicating a positive trend in the company’s financial health.
IPO Details and Pricing
The Gaudium IVF IPO price band has been set at ₹75–79 per share, valuing the company at approximately ₹575 crore. The offering comprises a fresh issue of 1.14 crore equity shares and an offer for sale (OFS) of nearly 95 lakh equity shares by promoter Manika Khanna. The IPO is open for subscription until February 24, with shares scheduled to be listed on the stock exchanges on February 27. The current grey market premium (GMP) stands at ₹8.5, suggesting that shares are trading at ₹87.5, a 10.76% increase over the IPO price band of ₹79, though the GMP has seen some fluctuation, previously reaching ₹15.
The Growing IVF Market in India
The timing of Gaudium IVF’s IPO coincides with a growing demand for assisted reproductive technologies in India. Factors contributing to this trend include increasing awareness of fertility treatments, delayed parenthood due to career aspirations, and rising instances of infertility. The company’s hub-and-spoke model is designed to address geographical barriers and provide accessible care to a wider population. Gaudium IVF’s commitment to affordability is also a key differentiator, aiming to make fertility treatments more accessible to a larger segment of the population.
The company’s success in attracting anchor investors and the strong initial subscription rate suggest a positive market reception. However, potential investors should carefully consider the risks and opportunities associated with investing in the IPO, including market volatility and the competitive landscape of the fertility care sector.
For those interested in learning more about the Gaudium IVF IPO, detailed information can be found on the BSE website and through financial news outlets covering the Indian stock market. Investors are encouraged to review the offer document carefully before making any investment decisions.
Disclaimer: I am a board-certified physician and medical writer, but this article is for informational purposes only and should not be considered financial or investment advice. Investing in IPOs carries inherent risks, and individuals should consult with a qualified financial advisor before making any investment decisions.
The listing of Gaudium IVF shares on February 27 will be a key moment for the company and the Indian fertility care sector. Investors and industry observers will be closely watching the performance of the stock and its impact on the broader market. Further updates on the IPO and the company’s future plans will be available through official announcements and financial reporting.
What are your thoughts on the Gaudium IVF IPO? Share your comments below and feel free to share this article with your network.
